Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
261.6 INR | -2.08% | -4.51% | +4.81% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
Sales 2024 * | 145B 1.74B | Sales 2025 * | 167B 2B | Capitalization | 319B 3.82B |
---|---|---|---|---|---|
Net income 2024 * | 9.49B 114M | Net income 2025 * | 9.3B 111M | EV / Sales 2024 * | 3.16 x |
Net Debt 2024 * | 139B 1.67B | Net Debt 2025 * | 142B 1.7B | EV / Sales 2025 * | 2.77 x |
P/E ratio 2024 * |
33.6
x | P/E ratio 2025 * |
37.4
x | Employees | 16,545 |
Yield 2024 * |
0.5% | Yield 2025 * |
0.55% | Free-Float | 37.3% |
Latest transcript on Biocon Limited
1 day | -2.08% | ||
1 week | -4.51% | ||
Current month | -0.95% | ||
1 month | +6.47% | ||
3 months | -5.23% | ||
6 months | +11.15% | ||
Current year | +4.81% |
Managers | Title | Age | Since |
---|---|---|---|
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 13-04-30 |
Peter Bains
CEO | Chief Executive Officer | 65 | 22-12-11 |
Chairman | 71 | 78-11-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 78-11-28 | |
Director/Board Member | 69 | 99-12-31 | |
Director/Board Member | 60 | 18-07-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.17% | 6 M€ | +6.07% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 261.6 | -2.08% | 5 476 389 |
24-04-18 | 267.2 | +1.31% | 9,499,931 |
24-04-16 | 263.8 | -0.57% | 3,484,465 |
24-04-15 | 265.2 | -3.19% | 4,071,926 |
24-04-12 | 274 | -1.55% | 6,929,503 |
Delayed Quote NSE India S.E., April 19, 2024 at 06:11 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.81% | 3.82B | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.25% | 21.66B | |
-18.35% | 20.77B | |
-8.31% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- BIOCON Stock